Valuation: Santhera Pharmaceuticals Holding AG

Market Cap 236M 292M 256M 221M 414M 27.53B 423M 2.84B 1.1B 13.61B 1.1B 1.07B 47.18B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 264M 326M 286M 247M 463M 30.76B 472M 3.17B 1.23B 15.2B 1.22B 1.2B 52.72B EV / Sales 2026 *
2.78x
EV / Sales 2027 * 2.23x
Free-Float
81.02%
Yield 2026 *
-
Yield 2027 * -
1 day-0.25%
1 week-0.75%
Current month-2.94%
1 month-1.12%
3 months+0.64%
6 months+22.64%
Current year+25.56%
1 week 15.5
Extreme 15.5
16.36
1 month 14.88
Extreme 14.88
17.88
Current year 11.7
Extreme 11.7
18.84
1 year 9.38
Extreme 9.38
18.84
3 years 7.14
Extreme 7.14
18.84
5 years 5
Extreme 5
28.2
10 years 5
Extreme 5
845
Manager TitleAgeSince
Chief Executive Officer 58 2019-11-30
Director of Finance/CFO 51 2025-02-23
Chief Operating Officer 55 2022-08-31
Director TitleAgeSince
Chairman 64 2022-06-29
Director/Board Member 58 2017-04-03
Director/Board Member 47 2023-06-26
Date Insider Type Main position Quantity % Market Cap.
24-01-21Buy 30,228 0.2396%
23-07-05Buy 2,000 0.0016%
22-01-10Buy 25,000 0.0458%
Change 5-day change 1-year change 3-year change Capi.($)
-0.50%-0.75%+31.18%+98.74% 291M
+1.75%+10.34%+61.63%+12.68% 310B
-0.92%+9.59%+30.45%-4.55% 72.76B
+3.57%+9.35%+43.61%+116.53% 8.62B
-0.43%+1.74%+2.97%-7.36% 8.29B
-6.43%-6.54%-10.28%-1.89% 4.5B
-6.42%+5.27%+0.68%+21.09% 3.83B
-6.87%-15.09%-34.90%+20.41% 3.45B
+2.95%+3.38%+47.39%+51.32% 2.6B
-4.41%+5.98%+8.04%-23.93% 2.12B
Average -1.74%+1.09%+18.08%+28.30% 41.63B
Weighted average by Cap. +1.02%+5.18%+52.12%+11.51%

Financials

2026 *2027 *
Net sales 94.7M 117M 103M 88.66M 166M 11.05B 170M 1.14B 440M 5.46B 440M 430M 18.94B 116M 143M 125M 108M 203M 13.49B 207M 1.39B 537M 6.67B 537M 525M 23.11B
Net income - -
Net Debt 27.7M 34.27M 30.05M 25.93M 48.63M 3.23B 49.64M 333M 129M 1.6B 129M 126M 5.54B 21.4M 26.48M 23.22M 20.03M 37.57M 2.5B 38.35M 257M 99.53M 1.23B 99.43M 97.25M 4.28B
Logo Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Employees
94
Date Price Change Volume
26-06-26 CHF 15.82 -0.50% 23,366
26-06-25 CHF 15.90 -0.38% 36,703
26-06-24 CHF 15.96 -0.62% 44,810
26-06-23 CHF 16.06 +0.63% 59,060
26-06-22 CHF 15.96 +0.13% 23,506
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
15.90CHF
Average target price
27.50CHF
Spread / Average Target
+72.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SANN Stock